Profile photo Nadia Haj Mohammad

Nadia Haj Mohammad

Assistant Professor - medical

Strategic program(s):

Biography

Dr. N. Haj Mohammad (1976) has been working as a medical oncologist in the UMC Utrecht since 2014. She studied pharmacy in the same city, and completed her pharmacy training in 2001. One year earlier, she started Medical school at the University of Amsterdam. She combined her training as a medical-oncologist at the AMC with PhD research in the clinical outcomes of treatments for gastroesophageal and pancreatic carcinoma.

She is member of the national guidelines for hepatocellular carcinoma and bile duct carcinoma. She is a board member of the Dutch Upper GI Cancer group.

Her research focuses on clinical outcomes of gastroesophageal and primary liver cancers. She is national PI of the phase 2 LyRICX study in metastatic gastroesophageal cancer and is local PI of multiple investigator and sponsor investigated studies within tumors of the upper digestive tract and primary liver tumors.

Strategic program(s):

Contact

Research groups

Primary Liver Tumors research group

Research aim

To improve surveillance, diagnostics, treatment, and outcome for patients with primary liver tumors (hepatocellular carcinoma and cholangiocarcinoma) by interdisciplinary and (inter-)national collaborative research

Go to group

Recent publications

Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer Sebastiaan N Siegerink, Steven C Kuijper, Tom van den Ende, Rob H A Verhoeven, Sjoerd G Elias, Nadia Haj Mohammad, Marije Slingerland, Sarah Derks, Hanneke W M van Laarhoven
Therapeutic Advances in Medical Oncology, 2026, vol. 18
Treatment strategies of esophageal cancer with concurrent cervical node metastasis Maxime E Sanders, Sylvia van der Horst, Teus J Weijs, Jan Erik Freund, Stella Mook, Nadia Haj Mohammad, Bianca Mostert, Bas P L Wijnhoven, Grard A P Nieuwenhuijzen, Hanneke W M van Laarhoven, Mark I van Berge Henegouwen, Misha D P Luyer, Pieter C van der Sluis, Rob H A Verhoeven, Sjoerd M Lagarde, Suzanne S Gisbertz, Jelle P Ruurda, Richard van Hillegersberg
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2026, vol. 39
The complication sum score M. L. Frederiks, M. Berbée, B. P.L. Wijnhoven, E. Schuit, P. S.N. van Rossum, G. J. Meijer, S. Mook, J. J.M.E. Nuyttens, H. Rütten, M. D. den Hartogh, B. van Etten, J. A. Langendijk, H. W.M. van Laarhoven, C. T. Muijs, C. T. Muijs, B. P.L. Wijnhoven, H. W.M. van Laarhoven, M. Berbee, J. A. Langendijk, H. P. van der Laan, A. van der Schaaf, J. J.M.E. Nuyttens, H. Rutten, Y. L.B. Klaver, M. L. Frederiks, R. H.A. Verhoeven, B. van Etten, J. J. de Haan, W. Kleder, M. I. van Berge Henegouwen, Z. van Kesteren, B. Mostert, W. Schillemans, M. Sosef, F. A.R.M. Warmerdam, R. Canters, J. P. Ruurda, N. Haj Mohammad, B. Klarenbeek, M. D. den Hartogh, H. Westdorp,
Clinical and translational radiation oncology, 2026, vol. 59
Socioeconomic disparities in treatment and survival of oesophageal and gastric cancer in the Netherlands Dillen C van der Aa, Mats D Teeken, Hanneke W M van Laarhoven, Suzanne S Gisbertz, Sjoerd M Lagarde, Nadia Haj Mohammad, Peter S N van Rossum, Rob H A Verhoeven, Mark I van Berge Henegouwen
The Lancet Regional Health - Europe, 2026, vol. 65
Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic gastroesophageal adenocarcinoma D Kamp, A M May, M J M van Velzen, S Mook, J E Freund, B Mostert, R H A Verhoeven, H W M van Laarhoven, N Haj Mohammad
British Journal of Cancer, 2026, vol. 134, p.1420-1428
Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Christina T Muijs, Maaike Berbee, Peter S N van Rossum, Nadia Haj Mohammad, Bas Wijnhoven, Hanneke W M Van Laarhoven, Karin M Haustermans
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026, vol. 44, p.1465-1467